SOX17: escape route from immune destruction in early CRC.
-
Authors
-
-
Papavassiliou, Kostas A1
-
Adamopoulos, Christos2
-
Papavassiliou, Athanasios G3
-
1
First University Department of Respiratory Medicine, 'Sotiria' Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
,
(Greece)
-
2
Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
,
(Greece)
-
3
Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece. Electronic address: [email protected].
,
(Greece)
- Type
- Published Article
- Journal
-
Trends in molecular medicine
- Publication Date
-
Jul 01, 2024
- Volume
-
30
- Issue
-
7
- Pages
-
609–611
- Identifiers
-
DOI: 10.1016/j.molmed.2024.04.001
-
PMID: 38594095
- Source
-
Medline
- Keywords
-
- Language
-
English
- License
-
Unknown
Abstract
In a recent report in Nature, Goto et al. reveal a novel immune-evasion mechanism adopted by early colorectal cancer (CRC) cells that is based on the transcription factor sex determining region Y (SRY)-box transcription factor 17 (SOX17). Leveraging colorectal adenoma and cancer models to perform comprehensive transcriptomic/chromatin analyses, this work shows that SOX17 generates immune-silent leucine-rich repeat-containing G protein-coupled receptor 5- (LGR5-) tumor cells, which suppress interferon gamma (IFNγ) signaling and promote immune escape. Copyright © 2024 Elsevier Ltd. All rights reserved.
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 08/11/2024 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at
https://www.ncbi.nlm.nih.gov/pubmed/38594095
Report this publication